EGFR and non-small cell lung carcinoma: For metastatic NSCLC and high-level <i>MET</i>amp, monotherapy with capmatinib, crizotinib, and tepotinib are recommended in the 2022 published NSCLC NCCN Guidelines.<h4>Conclusion</h4>Primary <i>MET</i>amp occurs in approximately 5% of NSCLC cases, and secondary <i>MET</i>amp in approximately 15% of cases previously treated with an EGFR inhibitor.